Verve Therapeutics (VERV.US): The 2024 Q1 financial report achieved revenue of US$5.695,000, with a previous value of US$1.404 million and an expected value of US$2.02 million; earnings per share were -0.59 dollars, previous value of -0.84 dollars, and expected value of -0.71 dollars.
Verve Therapeutics(VERV.US)：2024年Q1财报实现营收569.5万美元，前值为140.4万美元，预期值为202万美元；每股收益为-0.59美元，前值为-0.84美元，预期值为-0.71美元。
Verve Therapeutics (VERV.US): The 2024 Q1 financial report achieved revenue of US$5.695,000, with a previous value of US$1.404 million and an expected value of US$2.02 million; earnings per share were -0.59 dollars, previous value of -0.84 dollars, and ex
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.